The Crucial Roles of Th17-Related Cytokines/Signal Pathways in M
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
C19) United States C12) Patent Application Publication C10) Pub
1111111111111111 IIIIII IIIII 1111111111 11111 11111 111111111111111 1111111111 1111111111 11111111 US 20200081016Al c19) United States c12) Patent Application Publication c10) Pub. No.: US 2020/0081016 Al Talaat et al. (43) Pub. Date: Mar. 12, 2020 (54) BIOMARKERS FOR EARLY DIAGNOSIS Publication Classification AND DIFFERENTIATION OF (51) Int. Cl. MYCOBACTERIAL INFECTION GOIN 33/68 (2006.01) C12Q 116851 (2006.01) (71) Applicant: Wisconsin Alumni Research GOIN 33/569 (2006.01) Foundation, Madison, WI (US) (52) U.S. Cl. (72) Inventors: Adel Mohamed Talaat, Madison, WI CPC ......... GOIN 33/6854 (2013.01); GOIN 33/68 (US); Chia-wei Wu, Madison, WI (US) (2013.01); GOIN 2800/50 (2013.01); GOIN 33/5695 (2013.01); GOIN 2800/26 (2013.01); (21) Appl. No.: 16/555,819 C12Q 116851 (2013.01) (22) Filed: Aug. 29, 2019 (57) ABSTRACT Mycobacterial-specific biomarkers and methods of using Related U.S. Application Data such biomarkers for diagnosis of mycobacterial infection in (60) Provisional application No. 62/728,387, filed on Sep. a mammal are disclosed. 7, 2018. Specification includes a Sequence Listing. Patent Application Publication Mar. 12, 2020 Sheet 1 of 10 US 2020/0081016 Al FIG. 1 ·~{:: -{t i * !lpNbiNi$ 1 !lpN p~ra 111:111111 llillllll: 111!11,111llltllllll~ 11111 ■111 ~; C,,Nmnsus KR.IGINMTKX L.lC(X.AXXXXG AXXXXMPXTX RXO-GXVXXVG VKVXPWIPTX ® • ® l I I iipN lK>V(S ~Hl!lli!Wiofflij 1!11.llofJiillj mllB~lijftlt flol=fiolill ••t-il-~MM ~9 llpN p~ra HfHJoffit:torti ilffllGNillm miJllt~ttiollf ~•01:101111 llm:l:l1IA@~ iOO C,,nstmsus XXRXLXXGRS Vt IOGNT.LDP i LOt.MLSXXR XXGXOG.I...XVO ODXXXSR:AXM t2:;: i-/4~~ ! l 1 I~~~~b;:: llllil~l:1:1 llil 111111:1~:111~ 1111111::;1 1lllilllll: ~:~ C,,nimnsus XXXXXXXPGP QtHVDVXXI...X XPGPAGXIPA RHYRPXGGXX QXPt.l...VFYHG Consl:lrvat,ofl -:§;::. -
Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer
Downloaded from http://cshperspectives.cshlp.org/ on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer Juming Yan,1,2 Mark J. Smyth,2,3 and Michele W.L. Teng1,2 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston 4006, Queensland, Australia 2School of Medicine, University of Queensland, Herston 4006, Queensland, Australia 3Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston 4006, Queensland, Australia Correspondence: [email protected] The balance of proinflammatory cytokines interleukin (IL)-12 and IL-23 plays a key role in shaping the development of antitumor or protumor immunity. In this review, we discuss the role IL-12 and IL-23 plays in tumor biology from preclinical and clinical data. In particular, we discuss the mechanism by which IL-23 promotes tumor growth and metastases and how the IL-12/IL-23 axis of inflammation can be targeted for cancer therapy. he recognized interleukin (IL)-12 cytokine composition whereby the a-subunit (p19, Tfamily currently consists of IL-12, IL-23, p28, p35) and b-subunit (p40, Ebi3) are differ- IL-27, and IL-35 and these cytokines play im- entially shared to generate IL-12 (p40-p35), IL- portant roles in the development of appropriate 23 (p40-p19), IL-27 (Ebi3-p28), and IL-35 immune responses in various disease conditions (p40-p35) (Fig. 1A). Given their ability to share (Vignali and Kuchroo 2012). They act as a link a- and b-subunits, it has been predicted that between the innate and adaptive immune system combinations such as Ebi3-p19 and p28-p40 through mediating the appropriate differentia- could exist and serve physiological function tion of naı¨ve CD4þ T cells into various T helper (Fig. -
From IL-15 to IL-33: the Never-Ending List of New Players in Inflammation
From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble Aspirin and move ahead? Fulvio d’Acquisto, Francesco Maione, Magali Pederzoli-Ribeil To cite this version: Fulvio d’Acquisto, Francesco Maione, Magali Pederzoli-Ribeil. From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble Aspirin and move ahead?. Bio- chemical Pharmacology, Elsevier, 2009, 79 (4), pp.525. 10.1016/j.bcp.2009.09.015. hal-00544816 HAL Id: hal-00544816 https://hal.archives-ouvertes.fr/hal-00544816 Submitted on 9 Dec 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble Aspirin and move ahead? Authors: Fulvio D’Acquisto, Francesco Maione, Magali Pederzoli-Ribeil PII: S0006-2952(09)00769-2 DOI: doi:10.1016/j.bcp.2009.09.015 Reference: BCP 10329 To appear in: BCP Received date: 30-7-2009 Revised date: 9-9-2009 Accepted date: 10-9-2009 Please cite this article as: D’Acquisto F, Maione F, Pederzoli-Ribeil M, From IL- 15 to IL-33: the never-ending list of new players in inflammation. -
Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice Andrew P.R
ORIGINAL ARTICLE Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice Andrew P.R. Sutherland,1,2 Tom Van Belle,3 Andrea L. Wurster,1 Akira Suto,1 Monia Michaud,1 Dorothy Zhang,1 Michael J. Grusby,1,4 and Matthias von Herrath3 OBJECTIVE—Interleukin (IL)-21 is a type 1 cytokine that has known as insulin-dependent diabetes (idd) loci that confer been implicated in the pathogenesis of type 1 diabetes via the susceptibility to or protection from the development of unique biology of the nonobese diabetic (NOD) mouse strain. type 1 diabetes (2). Of the ϳ15 regions identified, idd3isof The aim of this study was to investigate a causal role for IL-21 in particular importance, because congenic NOD lines con- type 1 diabetes. taining alleles from protected strains at this locus are RESEARCH DESIGN AND METHODS—We generated IL- significantly less susceptible to diabetes. To date, idd3is 21R–deficient NOD mice and C57Bl/6 mice expressing IL-21 in the most potent disease modifying the non–major histo- pancreatic -cells, allowing the determination of the role of compatibility complex (MHC) locus (3). Therefore, some insufficient and excessive IL-21 signaling in type 1 diabetes. of the genes within the idd3 interval must play a crucial role in regulating immune destruction of pancreatic RESULTS—Deficiency in IL-21R expression renders NOD mice  resistant to insulitis, production of insulin autoantibodies, and -cells. onset of type 1 diabetes. The lymphoid compartment in IL- Among the several candidate genes within the idd3 21RϪ/Ϫ NOD is normal and does not contain an increased locus, interleukin (IL)-21 is of particular interest, because regulatory T-cell fraction or diminished effector cytokine re- dysregulated IL-21 production and signaling has been sponses. -
Interleukin 21 and Its Receptor Are Involved in NK Cell Expansion and Regulation of Lymphocyte Function
articles Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function Julia Parrish-Novak*, Stacey R. Dillon†, Andrew Nelson†, Angie Hammond*, Cindy Sprecher*, Jane A. Gross†, Janet Johnston†, Karen Madden*, Wenfeng Xu*, Jim West‡, Sara Schrader*, Steve Burkhead*, Mark Heipel*, Cameron Brandt*, Joseph L. Kuijper*, Janet Kramer*, Darrell Conklin§, Scott R. Presnell§, Jon Berry‡, Faith Shiota†, Susan Bort†, Kevin Hambly†, Sherri Mudri†, Chris Clegg†, Margaret Moorek, Francis J. Grant§, Catherine Lofton-Dayk, Teresa Gilbertk, Fenella Raymondk, Andrew Ching§, Lena Yaok, Deb Smithk, Philippa Websterk, Theodore Whitmorek, Mark Maurerk, Kenneth Kaushansky¶, Rick D. Holly* & Don Foster* Departments of * Functional Cloning, † Immunology, ‡ Protein Biochemistry, § Biomolecular Informatics, and k Genetics, ZymoGenetics, Inc., 1201 Eastlake Avenue E., Seattle, Washington 98102, USA ¶ Division of Hematology, Box 35 7710, University of Washington, School of Medicine, 1959 NE Pacific Street, Seattle, Washington 98195, USA ............................................................................................................................................................................................................................................................................ Cytokines are important in the regulation of haematopoiesis and immune responses, and can influence lymphocyte development. Here we have identified a class I cytokine receptor that is selectively expressed in lymphoid tissues and -
Interleukin (IL)17A, F and AF in Inflammation: a Study in Collageninduced Arthritis and Rheumatoid Arthritis
bs_bs_banner Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/cei.12376 Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis S. Sarkar,* S. Justa,* M. Brucks,* Summary J. Endres,† D. A. Fox,† X. Zhou,* Interleukin (IL)-17 plays a critical role in inflammation. Most studies to date F. Alnaimat,* B. Whitaker,‡ have elucidated the inflammatory role of IL-17A, often referred to as IL-17. J. C. Wheeler,‡ B. H. Jones§ and IL-17F is a member of the IL-17 family bearing 50% homology to IL-17A S. R. Bommireddy* and can also be present as heterodimer IL-17AF. This study elucidates the *Section of Rheumatology, Department of Medicine, and the Arizona Arthritis Center, distribution and contribution of IL-17A, F and AF in inflammatory arthritis. University of Arizona, Tucson, AZ, †Divison of Neutralizing antibody to IL-17A alone or IL-17F alone or in combination Rheumatology, Department of Internal Medicine, was utilized in the mouse collagen-induced arthritis (CIA) model to eluci- University of Michigan, Ann Arbor, MI, and date the contribution of each subtype in mediating inflammation. IL-17A, F ‡Biologics Research and §Immunology Discovery and AF were all increased during inflammatory arthritis. Neutralization of Research, Janssen Research and Development, IL-17A reduced the severity of arthritis, neutralization of IL-17A+IL-17F had Spring House, PA, USA the same effect as neutralizing IL-17A, while neutralization of IL-17F had no effect. Moreover, significantly higher levels of IL-17A and IL-17F were detected in peripheral blood mononuclear cells (PBMC) from patients with rheumatoid arthritis (RA) in comparison to patients with osteoarthritis (OA). -
Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes
Published OnlineFirst February 18, 2016; DOI: 10.1158/0008-5472.CAN-15-1548 Cancer Tumor and Stem Cell Biology Research Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor- Infiltrating Lymphocytes Geoffrey J. Markowitz1, Pengyuan Yang1,2,3, Jing Fu3, Gregory A. Michelotti4, Rui Chen1, Jianhua Sui5, Bin Yang2, Wen-Hao Qin3, Zheng Zhang6, Fu-Sheng Wang6, Anna Mae Diehl4, Qi-Jing Li7, Hongyang Wang3, and Xiao-Fan Wang1 Abstract Chronic inflammation in liver tissue is an underlying cause of IL18R1 deletion increased tumor burden. Mechanistically, we hepatocellular carcinoma. High levels of inflammatory cytokine foundthatIL18exertedinflammation-dependent tumor-sup- IL18 in the circulation of patients with hepatocellular carcinoma pressive effects largely by promoting the differentiation, activ- correlates with poor prognosis. However, conflicting results have ity, and survival of tumor-infiltrating T cells. Finally, differences been reported for IL18 in hepatocellular carcinoma development in the expression of IL18 in tumor tissue versus nontumor and progression. In this study, we used tissue specimens from tissueweremorepredictiveofpatientoutcomethanoverall hepatocellular carcinoma patients and clinically relevant mouse tissue expression. Taken together, our findings resolve a long- models of hepatocellular carcinoma to evaluate IL18 expression standing contradiction regarding a tumor-suppressive role for and function. In a mouse model of liver fibrosis that recapitulates IL18 in established hepatocellular carcinoma and provide a a tumor-promoting microenvironment, global deletion of the mechanistic explanation for the complex relationship between IL18 receptor IL18R1 enhanced tumor growth and burden. Sim- its expression pattern and hepatocellular carcinoma prognosis. ilarly, in a carcinogen-induced model of liver tumorigenesis, Cancer Res; 76(8); 1–12. -
Interleukin-33 Signaling Exacerbates Experimental Infectious Colitis by Enhancing Gut Permeability and Inhibiting Protective Th17 Immunity
www.nature.com/mi ARTICLE OPEN Interleukin-33 signaling exacerbates experimental infectious colitis by enhancing gut permeability and inhibiting protective Th17 immunity Vittoria Palmieri1, Jana-Fabienne Ebel1, Nhi Ngo Thi Phuong1, Robert Klopfleisch2, Vivian Pham Vu3,4, Alexandra Adamczyk1, Julia Zöller1, Christian Riedel5, Jan Buer1, Philippe Krebs3, Wiebke Hansen1, Eva Pastille1 and Astrid M. Westendorf 1 A wide range of microbial pathogens is capable of entering the gastrointestinal tract, causing infectious diarrhea and colitis. A finely tuned balance between different cytokines is necessary to eradicate the microbial threat and to avoid infection complications. The current study identified IL-33 as a critical regulator of the immune response to the enteric pathogen Citrobacter rodentium.We observed that deficiency of the IL-33 signaling pathway attenuates bacterial-induced colitis. Conversely, boosting this pathway strongly aggravates the inflammatory response and makes the mice prone to systemic infection. Mechanistically, IL-33 mediates its detrimental effect by enhancing gut permeability and by limiting the induction of protective T helper 17 cells at the site of infection, thus impairing host defense mechanisms against the enteric pathogen. Importantly, IL-33-treated infected mice supplemented with IL-17A are able to resist the otherwise strong systemic spreading of the pathogen. These findings reveal a novel IL-33/IL-17A crosstalk that controls the pathogenesis of Citrobacter rodentium-driven infectious colitis. Manipulating the dynamics of cytokines may offer new therapeutic strategies to treat specific intestinal infections. 1234567890();,: Mucosal Immunology (2021) 14:923–936; https://doi.org/10.1038/s41385-021-00386-7 INTRODUCTION epithelial cells, and endothelial cells in response to injury6. -
T Cell–Derived IL-22 Amplifies IL-1B–Driven Inflammation in Human Adipose Tissue
1966 Diabetes Volume 63, June 2014 Elise Dalmas,1,2,3,4 Nicolas Venteclef,1,2,3,4 Charles Caer,1,2,3,4 Christine Poitou,1,2,3,4,5 Isabelle Cremer,1,2,3 Judith Aron-Wisnewsky,1,2,3,4,5 Sébastien Lacroix-Desmazes,1,2,3 Jagadeesh Bayry,1,2,3 Srinivas V. Kaveri,1,2,3 Karine Clément,1,2,3,4,5 Sébastien André,1,2,3,4 and Michèle Guerre-Millo1,2,3,4 T Cell–Derived IL-22 Amplifies IL-1b–Driven Inflammation in Human Adipose Tissue: Relevance to Obesity and Type 2 Diabetes Diabetes 2014;63:1966–1977 | DOI: 10.2337/db13-1511 Proinflammatory cytokines are critically involved in the combined anti-IL-1b and anti-IL-22 immunotherapy alteration of adipose tissue biology leading to deteri- in human obesity. oration of glucose homeostasis in obesity. Here we show a pronounced proinflammatory signature of adi- pose tissue macrophages in type 2 diabetic obese pa- A causal relationship between macrophage accumulation in tients, mainly driven by increased NLRP3-dependent adipose tissue and systemic insulin resistance has been interleukin (IL)-1b production. IL-1b release increased clearly established in mouse studies, in which macrophage with glycemic deterioration and decreased after gas- abundance can be manipulated through diet, genetic, or tric bypass surgery. A specific enrichment of IL-17- pharmacological intervention (1–3). In humans, however, + OBESITY STUDIES and IL-22-producing CD4 T cells was found in adipose the amount of adipose tissue macrophages is not consis- tissue of type 2 diabetic obese patients. -
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
Author Manuscript Published OnlineFirst on May 19, 2020; DOI: 10.1158/1078-0432.CCR-19-1086 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. The interleukin 22 pathway interacts with mutant KRAS to promote poor prognosis in colon cancer Authors: Sarah McCuaig1, David Barras,2, Elizabeth Mann1, Matthias Friedrich1, Samuel Bullers1, Alina Janney1, Lucy C. Garner1, Enric Domingo3, Viktor Hendrik Koelzer3,4,5, Mauro Delorenzi2,6,7, Sabine Tejpar8, Timothy Maughan9, Nathaniel R. West1, Fiona Powrie1 Affiliations: 1 Kennedy Institute of Rheumatology, University of Oxford, Oxford UK. 2 SIB Swiss Institute of Bioinformatics, Bioinformatics Core Facility, Lausanne, Switzerland. 3Department of Oncology, University of Oxford, Oxford UK. 4Nuffield Department of Medicine, University of Oxford, Oxford UK. 5Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Zurich Switzerland. 6 Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland. 7 Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne Switzerland. 8 Molecular Digestive Oncology, KU Leuven, Belgium. 9 CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 19, 2020; DOI: 10.1158/1078-0432.CCR-19-1086 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Correspondence to: Professor Fiona Powrie; Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7YF, UK. Email: [email protected] Conflicts of Interest: S.M., N.R.W., and F.P. -
IL-1 Secretion Innate T Cell Responses Through Effects On
Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion This information is current as Celia Peral de Castro, Sarah A. Jones, Clíona Ní Cheallaigh, of September 24, 2021. Claire A. Hearnden, Laura Williams, Jan Winter, Ed C. Lavelle, Kingston H. G. Mills and James Harris J Immunol 2012; 189:4144-4153; Prepublished online 12 September 2012; doi: 10.4049/jimmunol.1201946 Downloaded from http://www.jimmunol.org/content/189/8/4144 Supplementary http://www.jimmunol.org/content/suppl/2012/09/12/jimmunol.120194 Material 6.DC1 http://www.jimmunol.org/ References This article cites 48 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/189/8/4144.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion Celia Peral de Castro,*,† Sarah A. -
IL-1Β Induces the Rapid Secretion of the Antimicrobial Protein IL-26 From
Published June 24, 2019, doi:10.4049/jimmunol.1900318 The Journal of Immunology IL-1b Induces the Rapid Secretion of the Antimicrobial Protein IL-26 from Th17 Cells David I. Weiss,*,† Feiyang Ma,†,‡ Alexander A. Merleev,x Emanual Maverakis,x Michel Gilliet,{ Samuel J. Balin,* Bryan D. Bryson,‖ Maria Teresa Ochoa,# Matteo Pellegrini,*,‡ Barry R. Bloom,** and Robert L. Modlin*,†† Th17 cells play a critical role in the adaptive immune response against extracellular bacteria, and the possible mechanisms by which they can protect against infection are of particular interest. In this study, we describe, to our knowledge, a novel IL-1b dependent pathway for secretion of the antimicrobial peptide IL-26 from human Th17 cells that is independent of and more rapid than classical TCR activation. We find that IL-26 is secreted 3 hours after treating PBMCs with Mycobacterium leprae as compared with 48 hours for IFN-g and IL-17A. IL-1b was required for microbial ligand induction of IL-26 and was sufficient to stimulate IL-26 release from Th17 cells. Only IL-1RI+ Th17 cells responded to IL-1b, inducing an NF-kB–regulated transcriptome. Finally, supernatants from IL-1b–treated memory T cells killed Escherichia coli in an IL-26–dependent manner. These results identify a mechanism by which human IL-1RI+ “antimicrobial Th17 cells” can be rapidly activated by IL-1b as part of the innate immune response to produce IL-26 to kill extracellular bacteria. The Journal of Immunology, 2019, 203: 000–000. cells are crucial for effective host defense against a wide and neutrophils.